Join, Jeff Blaney (Genentech), Darren Green (GSK), Julian Levell (New Equilibrium), Matt Segall (Optibrium) who will discuss the state of AI in early drug discovery from hit to preclinical candidate and share their experiences with and expectations of AI.
AI in early Drug Discovery: From Promise to Practice
Recent Comments